Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(17%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

50%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

3(50.0%)

Phase 2Efficacy & side effects

3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(3)

Detailed Status

Completed3

Not yet recruiting2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (50.0%)

Phase 23 (50.0%)

Trials by Status

recruiting117%

completed350%

not_yet_recruiting233%

Recent Activity

1 active trials

Showing 5 of 6

not_yet_recruitingphase_1

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

NCT07444606

not_yet_recruitingphase_2

Clinical Trials (6)

Showing 6 of 6 trials

NCT07444606Phase 1

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

Not Yet Recruiting

NCT07424092Phase 2

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

Not Yet Recruiting

NCT05009992Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Recruiting

NCT03178032Phase 1

Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas

Completed

NCT02798406Phase 2

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Completed

NCT00805376Phase 1

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6